Current Neuro-Oncology
Volume
28 Number 2
20 January 2026
Home > Publications > Current Neuro-Oncology > Volume 28, Year 2026 > Number 2, 20 January
Salama
AKS, Wang V, Macrae ER, Park JI, Chen HX, Gray RJ, McShane LM,
Rubinstein LV, Patton D, Williams PM, Hamilton SR, Armstrong DK,
Tricoli JV, Conley BA, Arteaga CL, Harris LN, O'Dwyer PJ, Chen AP,
Flaherty KT.
Phase
II Study of Dabrafenib and Trametinib in Patients With Tumors With
BRAFV600E
Mutations: Updated Results From NCI-MATCH ECOG-ACRIN Trial
(EAY131) Subprotocol H.
JCO
Precis Oncol.
2026 Jan
14;10:e2500338.
doi:
10.1200/PO-25-00338. PMID:
41533998. Interventional
study. ˍ
Diao
Y, Liang H, Wang Y, Hang L, Fang L, Qu H, Sun H, Li W, Jiang G.
Exploring
the diagnostic value of dynamic contrast-enhanced and diffusion
tensor imaging of intratumoural and peritumoural high-grade
gliomas for distinguishing treatment response from tumour
progression.
Clin
Radiol.
2025 Oct 7;93:107114. doi:
10.1016/j.crad.2025.107114. PMID:
41529314. Observational
study. ˍ
Rocha
Grade D, Soares T, João DA, Lima T, Marques Baptista A.
Extremely
Long-Term Glioblastoma Survival (Ten Years): A Possible Role of
Immune Modulation From Pre-existing Diseases.
Cureus.
2025 Dec 11;17(12):e98984. doi:
10.7759/cureus.98984. PMID:
41523441. Case
report. ˍ
Tong
Y, Rao H, Li Y, Chang C, Yang Y.
Efficacy
and survival outcomes of bevacizumab plus minocycline for
glioblastoma.
Am
J Transl Res.
2025 Dec 15;17(12):9846-9858. doi:
10.62347/LDSW5672. PMID:
41552322. Observational
study. ˍ